 |
Top Story
The Pathway to Public Rx Price Controls in 2016
The issue of drug price controls in public prescription programs has long been a point of contention. But today, writes Tom Norton, as several historical and contemporary factors continue to line up, we may be on a pathway to changing that. In fact, we may take major steps towards Rx price controls for all public drug programs as early as 2016
...Read more |
While the regulatory environment has been evolving over the past few years and conducting business under the Sunshine law has been challenging, submissions published during the course of 2013 and 2014 highlighted some best practices life sciences companies can use to develop a tactical roadmap to address aggregate spend needs. Learn more about these best practices in a new IMS Health white paper.
 Download now |
Comment
Pharma Ties to American Heart Association Scrutinized
UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, has questioned pharma's connections to the influential and highly visible American Heart Association (AHA). Clearly, it's necessary to keep an eye on dollars and influence, writes Casey McDonald, but UNITE's claims of influence bought or anything more sinister are far from substantiated
...Read more |
Find new partners at the AAPS Annual Meeting & Exposition!
The largest, global business forum for pharmaceutical and biopharmaceutical manufacturers, distributors, and service providers is happening October 26-28, 2016, in Orlando, Florida.
Special registration pricing available for full access to the 80,000 net square feet of exposition floor space. Visit  www.aaps.org/annualmeeting for complete information.
|
Global
England’s Cancer Drug Fund: Will Patients Pay the Price for Being at the Back of the Line?
The headlines in England about the Cancer Drug Fund are no longer about the thousands of patients benefiting from new cancer therapies paid for by the fund. Instead they’re about the thousands who will now lose out the number of drugs and indications are cut by NHS England: from 84 therapies at the beginning of 2015 to 41 by November this year. Leela Barham reports
...Read more |
Pharmaceutical Executive E-Book – Coming November 2015: Securing the Global Supply Chain: Strategies for Operational Excellence
Key Topics include:
- Compliance Groundswell: What are the New Rules and Regulator Expectations?
- Global Dynamics of Risk: Can Technology Keep Pace?
- Benchmarking Best Practices: Upgrading Company Performance Culture
- What's Ahead: How Logistics and Distribution Science will Shape Tomorrow's Supply Chain
 Contact your sales rep for more information and to secure your sponsorship. |
Social Media
Gilead’s $10 Billion Worth of Problems: PharmExec’s Top Tweets
Biopharma investment pundits have been having a field day, all but certain that Gilead will make a big (possibly transformative) move soon. Casey McDonald looks at reactions in the Twittersphere
...Read more |
Pharmaceutical Executive E-Book – Coming October 2015: Changing Contours of Commercialization: Impact of US Health Reform on Patients, Payers and Providers
Key Topics include:
- Phase-in of the 2010 Affordable Care Act: Five stages of pain and plenty
- Pay for Performance and Shared Savings Programs – Implications for Pharma Marketers
- How ACO models are driving physician and provider decision-making
- Primer on policies and financial drivers impacting payer markets – MLR, MSSP, CMS etc.
 Contact your sales rep for more information and to secure your sponsorship. |
From Pharm Exec Magazine
Pharm Exec’s 14th Annual Industry Audit
If it was any other year, Pharm Exec’s 2014 Industry Audit results would be considered as a standout performance. But coming just on the heels of the industry’s spectacular revenue run up in 2013-2012, it dims a bit in comparison. But in a global business environment marked by collaborative, cross-sector relationships, it shows that biopharmaceuticals continue to lead other industries by outpacing the overall growth in the US economy
...Read more |
New tufts CSDD Research
Industry Adoption of eClinical Solutions and CDISC Standards
LIVE WEBCAST: Thursday, October 8, 2015 at 11:00 am ET
 Register for free
|
 |
 //Pfenex (San Diego, CA) announced that Dennis M. Fenton, Ph.D., has been appointed to the company's Board of Directors.//Klick Health (Toronto, ON) confirmed that its Co-founder and CEO Leerom Segal has been appointed to the Google Health Advisory Board.//BioBlast Pharma (New Haven CT) appointed Paul Firuta to the newly created position of Chief Commercial Officer. //Radius Health (Waltham, MA) hired David P. Snow as Chief Commercial Office.// |
|
|
